- Home
- LPTX vs CNF Comparison
LPTX vs CNF Comparison
Compare LPTX & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CNF
- Stock Information
- Founded
- LPTX 2011
- CNF 1999
- Country
- LPTX United States
- CNF China
- Employees
- LPTX N/A
- CNF N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CNF Finance: Consumer Services
- Sector
- LPTX Health Care
- CNF Finance
- Exchange
- LPTX Nasdaq
- CNF Nasdaq
- Market Cap
- LPTX 99.5M
- CNF 89.2M
- IPO Year
- LPTX N/A
- CNF 2018
- Fundamental
- Price
- LPTX $3.11
- CNF $0.89
- Analyst Decision
- LPTX Strong Buy
- CNF
- Analyst Count
- LPTX 3
- CNF 0
- Target Price
- LPTX $7.50
- CNF N/A
- AVG Volume (30 Days)
- LPTX 437.3K
- CNF 44.7K
- Earning Date
- LPTX 11-13-2024
- CNF 12-24-2024
- Dividend Yield
- LPTX N/A
- CNF N/A
- EPS Growth
- LPTX N/A
- CNF N/A
- EPS
- LPTX N/A
- CNF 0.24
- Revenue
- LPTX N/A
- CNF $109,788,152.00
- Revenue This Year
- LPTX N/A
- CNF N/A
- Revenue Next Year
- LPTX N/A
- CNF $13.09
- P/E Ratio
- LPTX N/A
- CNF $4.00
- Revenue Growth
- LPTX N/A
- CNF 12.99
- 52 Week Low
- LPTX $1.68
- CNF $0.81
- 52 Week High
- LPTX $5.00
- CNF $2.84
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- CNF 39.78
- Support Level
- LPTX $2.87
- CNF $0.81
- Resistance Level
- LPTX $3.12
- CNF $0.95
- Average True Range (ATR)
- LPTX 0.28
- CNF 0.07
- MACD
- LPTX 0.02
- CNF 0.01
- Stochastic Oscillator
- LPTX 49.42
- CNF 25.93
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.